News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Discovery Laboratories (DSCO) to Report Second Quarter 2013 Results and Hold Conference Call on Thursday, August 8, 2013



7/25/2013 7:27:57 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WARRINGTON, Pa., July 25, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO) will report second quarter 2013 results on Thursday, August 8, 2013 before the open of the U.S. financial markets. The Company will also host a conference call at 10:00 a.m. ET that same day to discuss the second quarter financial results and other business updates. A question-and-answer session will follow managements' remarks.

To access the conference call and participate in the question-and-answer session, the number for domestic callers is (877) 215-0093 and for international callers (706) 679-3237. The conference call passcode is 20041973. An audio replay of the conference call will be available until September 8, 2013. The replay number is (855) 859-2056 or (404) 537-3406 using the same conference call password listed above.

The audio webcast of the conference call will be available on the Discovery Labs website at www.discoverylabs.com. It is recommended that participants log onto the audio webcast at least 15 minutes prior to the call. A replay of the audio webcast will be available for up to 45 days after the call at the Company's website.

About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant. Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs' strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, significantly expand the current worldwide RDS market.

For more information, please visit the Company's website at www.discoverylabs.com.

SOURCE Discovery Laboratories, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES